The Evidence for Omega-3 Supplementation
Cardiovascular disease: the evidence for omega-3 supplementation in cardiovascular risk reduction is complex and has evolved significantly. Earlier trials using lower doses (1g EPA+DHA daily) showed mixed results. The landmark REDUCE-IT trial (2018) using 4g daily of high-purity EPA (icosapentaenoic acid ethyl ester, brand name Vascepa) in patients with elevated triglycerides and established cardiovascular disease or diabetes showed 25% reductions in major adverse cardiovascular events including a striking 28% reduction in cardiovascular death. The STRENGTH trial using 4g of an EPA+DHA combination showed no benefit, suggesting that EPA alone may have unique cardioprotective mechanisms. Current cardiology guidelines recommend high-dose EPA for high-risk patients with elevated triglycerides.
Depression: omega-3s have compelling evidence as both preventive and adjunctive treatment for depression. A 2019 meta-analysis of 26 RCTs found significant antidepressant effects of omega-3 supplementation, with EPA-dominant formulations showing stronger effects than DHA-dominant. The mechanism involves anti-inflammatory pathways (depression has a significant inflammatory component in at least 40% of patients), modulation of monoamine neurotransmitter systems, and enhancement of brain-derived neurotrophic factor (BDNF), the “Miracle-Gro” for neurons that promotes neurogenesis and synaptic plasticity. Omega-3 supplementation is particularly beneficial as an adjunct to antidepressants rather than a standalone treatment, with combination producing superior outcomes to either alone.
Cognitive decline and dementia: large prospective studies consistently show associations between higher omega-3 status and reduced dementia risk, with the MIDAS trial showing that 900mg DHA daily for 24 weeks significantly improved episodic memory in older adults with age-related cognitive decline. However, trials in patients with established Alzheimer’s disease show minimal benefit, suggesting that omega-3s are primarily preventive rather than therapeutic for dementia — making adequate intake throughout life, not just at disease onset, the relevant intervention. Children with ADHD show improvements in attention and behavior with omega-3 supplementation in several meta-analyses, consistent with DHA’s critical role in frontal lobe function.
Inflammation and chronic disease: EPA and DHA are the precursors to resolvins, protectins, and maresins — a class of lipid mediators discovered in the 2000s by Charles Serhan at Harvard that actively resolve inflammation (rather than merely suppressing it). This resolution of inflammation pathway represents a fundamentally different anti-inflammatory mechanism from NSAIDs or corticosteroids, which merely block inflammation. Clinical benefits include reductions in inflammatory markers (CRP, IL-6, TNF-alpha) and clinical improvements in conditions driven by chronic inflammation: rheumatoid arthritis (significant pain reduction, reduced NSAID requirements), Crohn’s disease (improved remission rates), and atopic eczema.